ArticleEuropean journal of neurology2025
GLP-1 Agonists as Potential Neuromodulators in Development of Parkinson's Disease: A Nationwide Cohort Study.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Glucagon-like peptide-1 receptor agonists and the risk of Parkinson's disease in patients with type 2 diabetes: a systematic review and meta-analysis of large-scale real-world data.Frontiers in endocrinology · 2026Pooled it
- Research hotspots and trends of GLP-1 receptor agonists in the treatment of Parkinson's disease: a bibliometric analysis.Frontiers in neuroscience · 2026Pooled it
- From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson's disease. A systematic review and meta-analysis of placebo-controlled trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Beyond Glycemic Control: GLP-1RA-Based Therapies and Emerging Targets Beyond the Metabolic Axis.Journal of clinical medicine · 2026Review
- Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- An Update on GLP-1 Receptor Agonists.Journal of diabetes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundParkinson's disease is a progressive neurodegenerative disorder with no cure. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may have neuroprotective effects. However, long-term real-world studies are needed to clarify their potential impact on Parkinson's disease.
methodsThis nationwide cohort study included 33,462 patients (16,731 GLP-1RA initiators and 16,731 propensity score-matched dipeptidyl peptidase-4 inhibitor [DPP-4i] initiators) from 2007 to 2018, followed until 2022. Eligible participants were ≥ 50 years, had no prior cancer or Parkinson's disease, and were residents in Denmark for at least 10 years. Patients were followed until Parkinson's diagnosis, death, emigration, treatment discontinuation (no additional prescription within 180 days), switch to the other study drug, or end of follow-up. Additional analyses included comparisons with insulin, competing risk of death, and the main analysis disregarding adherence.
resultsDuring follow-up, 192 patients developed Parkinson's disease, including 93 during sustained treatment. After 10 years, sustained GLP-1RA users had a lower hazard ratio (HR 0.57 (95% CI 0.37;0.85)) and absolute risk difference (-0.24 (95% CI -0.63 to 0.15)) compared to DPP-4i users. Similar trends were found when using insulin as a comparator. A significant survival advantage was found among sustained users of GLP-1RA (particularly when comparing with insulin). When not accounting for adherence, the results was not statistically significant.
conclusionsResults were suggestive for a potential neuroprotective effect of GLP-1RAs against Parkinson's disease. Further studies are needed to assess biomarkers of disease progression, and evaluate safety in patients with Parkinson's disease, dosing, and effects when combined with other treatments in neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.